Drug General Information
Drug ID
D0N8QK
Former ID
DNCL001986
Drug Name
ABT-288
Drug Type
Small molecular drug
Indication Alzheimer disease; Schizophrenia [ICD9: 331, 295; ICD10:G30, F20] Phase 2 [522864], [541972]
Company
Abbott Laboratories
Structure
Download
2D MOL
Formula
C23H24N4O
InChI
InChI=1S/C23H24N4O/c1-25-15-19-12-14-26(22(19)16-25)20-8-4-17(5-9-20)18-6-10-21(11-7-18)27-23(28)3-2-13-24-27/h2-11,13,19,22H,12,14-16H2,1H3/t19-,22+/m1/s1
InChIKey
GNIRITULTPTAQW-KNQAVFIVSA-N
PubChem Compound ID
PubChem Substance ID
Target and Pathway
Target(s) Histamine H3 receptor Target Info Modulator
KEGG Pathway Neuroactive ligand-receptor interaction
Reactome Histamine receptors
G alpha (i) signalling events
WikiPathways Monoamine Transport
GPCRs, Class A Rhodopsin-like
GPCR ligand binding
GPCR downstream signaling
References
Ref 522864ClinicalTrials.gov (NCT01018875) Efficacy and Safety Study of ABT-288 in Subjects With Mild-to-Moderate Alzheimer's Disease. U.S. National Institutes of Health.
Ref 541972(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6927).

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.